226 related articles for article (PubMed ID: 27319235)
1. [Use of new drugs within primary therapy of multiple myeloma].
Štork M; Krejčí M; Sandecká V; Král Z; Pour L
Vnitr Lek; 2016; 62(5):413-22. PubMed ID: 27319235
[TBL] [Abstract][Full Text] [Related]
2. [First-line treatment of multiple myeloma].
Breitkreutz I; Raab M; Goldschmidt H
Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
4. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
5. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
6. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
Lee HS; Min CK
Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma: is a shift toward continuous therapy needed to move forward?
Guglielmelli T; Palumbo A
Expert Rev Hematol; 2015 Jun; 8(3):253-6. PubMed ID: 25582032
[TBL] [Abstract][Full Text] [Related]
8. [Lenalidomid (Revlimid) in the treatment of multiple myeloma--first experience in the Czech Republic].
Novotová E; Neuwirtová R; Jonásová A; Straub J; Spicka I
Cas Lek Cesk; 2008; 147(12):623-6. PubMed ID: 19235487
[TBL] [Abstract][Full Text] [Related]
9. Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I; Gertz M
Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Mian M; Tinelli M; DE March E; Turri G; Meneghini V; Pescosta N; Berno T; Marabese A; Mondello P; Patriarca F; Pizzolo G; Semenzato G; Cortelazzo S; Zambello R
Anticancer Res; 2016 Mar; 36(3):1059-65. PubMed ID: 26976998
[TBL] [Abstract][Full Text] [Related]
11. Stem Cell Transplantation in Multiple Myeloma.
Offidani M; Gentili S; Gay F; Aghemo E; Maracci L; Corvatta L; Palumbo A
Curr Cancer Drug Targets; 2017; 17(9):769-781. PubMed ID: 27659429
[TBL] [Abstract][Full Text] [Related]
12. Stem cell transplantation for multiple myeloma: current and future status.
Giralt S
Hematology; 2012 Apr; 17 Suppl 1():S117-20. PubMed ID: 22507797
[TBL] [Abstract][Full Text] [Related]
13. [Current treatment strategies for multiple myeloma].
Mey UJ
Ther Umsch; 2010 Oct; 67(10):527-35. PubMed ID: 20886459
[TBL] [Abstract][Full Text] [Related]
14. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
17. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
18. Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
Migkou M; Gavriatopoulou M; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2018 Jun; 11(6):463-469. PubMed ID: 29788798
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.
Shank BR; Brown VT; Schwartz RN
J Oncol Pharm Pract; 2015 Feb; 21(1):36-51. PubMed ID: 24395544
[TBL] [Abstract][Full Text] [Related]
20. Frontline treatment of multiple myeloma.
Fonseca R
Hematology; 2012 Apr; 17 Suppl 1():S101-4. PubMed ID: 22507793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]